Updates are available Correction dated 2022-09-07
Click to view Correction: https://doi.org/10.1186/s10194-022-01487-9
-
Authors
Rosignoli, Chiara
Ornello, Raffaele
Onofri, Agnese
Caponnetto, Valeria
Grazzi, Licia
Raggi, Alberto
Leonardi, Matilde
Sacco, Simona
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 2 August 2022
First Online: 11 August 2022
Change Date: 7 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s10194-022-01487-9
Declarations
:
: Not applicable.
: Not applicable.
: R.O. reports personal fees from Novartis, Teva, and Eli Lilly, and had non-financial relationships with Allergan/AbbVie, Novartis and Teva. S.S. reports personal fees or nonfinancial support from Allergan, Abbott, Eli Lilly, Novartis, Teva, Medscape, Bayer, Pfizer, Medtronic, Starmed, Bristol-Myers Squibb, and Daiichi Sankyo. L.G. has received consultancy and advisory fees from Allergan SpA, TEVA Pharm, Eli lilly, Novartis AG. A.O., V.C., C.R., M.L. and A.R. report no competing interest.
